Expertise in
62
conditions

Dr. Abhinav Chandra

Hematology
Yuma Regional Medical Center Cancer Cent
2375 S Ridgeview Dr, 
Yuma, AZ 
Offers Telehealth
Expertise in
62
conditions
Yuma Regional Medical Center Cancer Cent
2375 S Ridgeview Dr, 
Yuma, AZ 

Overview

Abhinav Chandra is a Hematologist practicing medicine in Yuma, Arizona.

Dr. Chandra is highly rated in 62 conditions, according to our data. His clinical expertise encompasses Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Myelodysplastic Syndrome (MDS), and Thrombocytopenia.

He is actively involved in clinical research, co-authoring 40 peer reviewed articles and participating in 7 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in NY

Hospital Affiliations

Yuma Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Yuma Regional Medical Center Cancer Cent
2375 S Ridgeview Dr, Yuma, AZ 85364
Other Locations
Yuma Regional Medical Center
2400 S Avenue A, Yuma, AZ 85364

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Daratumumab, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma
A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Bortezomib, Lenalidomide, Dexamethasone
Study Phase: Phase 1
Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant Chemotherapy
Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant Chemotherapy
Enrollment Status: Unknown
Publish Date: December 18, 2023
Intervention Type: Biological, Other
Study Drugs: Pertuzumab, Sargramostim, Trastuzumab, Trastuzumab Emtansine, Vaccine Therapy
Study Phase: Phase 2
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab
Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab
Enrollment Status: Withdrawn
Publish Date: May 26, 2022
Intervention Type: Drug, Biological
Study Drugs: Abemaciclib, Trastuzumab Emtansine
Study Phase: Phase 2
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
View 6 Less Clinical Trials

40 Total Publications

A Case of Solitary Amyloid Lung Nodule Treated With Surgery.
A Case of Solitary Amyloid Lung Nodule Treated With Surgery.
Journal: Cureus
Published: August 16, 2024
Similar Doctors
Expertise in
32
conditions
Dr. Augustine Lau
Hematology
Expertise in
32
conditions
Dr. Augustine Lau
Hematology
Referral may be required

Yuma Regional Medical Center Cancer Cent

2375 S Ridgeview Dr, 
Yuma, AZ 
 (1.5 miles away)
928-317-2518
Languages Spoken:
English

Augustine Lau is a Hematologist practicing medicine in Yuma, Arizona. Dr. Lau is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Chronic Familial Neutropenia, Agranulocytosis, Clear Cell Sarcoma, and WT1-Related Wilms Tumor Syndromes.

Expertise in
5
conditions
Dr. Gregory Yang
Hematology
Expertise in
5
conditions
Dr. Gregory Yang
Hematology
Referral may be required

Yuma Regional Plaza Laboratory

1320 W 24th St, 
Yuma, AZ 
 (1.8 miles away)
928-317-2518
Languages Spoken:
English
See accepted insurances

Gregory Yang is a Hematologist practicing medicine in Yuma, Arizona. Dr. Yang is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Inflammatory Breast Cancer, Breast Cancer, and Angiosarcoma.

Expertise in
14
conditions
Dr. Antonio Fontelonga
Hematology
Expertise in
14
conditions
Dr. Antonio Fontelonga
Hematology
Referral may be required

Office

1385 S Pacific Ave, 
Yuma, AZ 
 (3.5 miles away)
928-314-1174
Languages Spoken:
English
See accepted insurances

Antonio Fontelonga is a Hematologist practicing medicine in Yuma, Arizona. Dr. Fontelonga is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Inflammatory Breast Cancer, Breast Cancer, Angiosarcoma, and Paget Disease of the Breast.

Frequently Asked Questions about Dr. Abhinav Chandra

How do I make an appointment with Dr. Abhinav Chandra?

You can book an appointment with Dr. Abhinav Chandra by calling their office at 928-317-2518. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Abhinav Chandra a top-rated expert for Adult Immune Thrombocytopenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Abhinav Chandra is classified as an Distinguished expert for Adult Immune Thrombocytopenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Abhinav Chandra specialize in?

While Dr. Abhinav Chandra is a Hematology, they have specific expertise in Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, and Myelodysplastic Syndrome (MDS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Abhinav Chandra participate in research or clinical trials?

Yes. Dr. Abhinav Chandra has published 40 articles and abstracts on conditions like Adult Immune Thrombocytopenia. You can view a list of Dr. Abhinav Chandra's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Abhinav Chandra accept my insurance?

Dr. Abhinav Chandra accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 928-317-2518 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chandra's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 54 Advanced Conditions
    View All 114 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile